Title
Clinical Application and Basic Study of Medicinal Fractions-based Herbal Combinations
Clinical Application and Basic Study of Medicinal Fractions-based Herbal Combinations:A Prospective Randomized Controlled Multi-site Clinical Trial About Fractions-based Herbal Combinations of Clearing Heat and Promoting Blood Circulation
Phase
N/AStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Ischemic StrokeIntervention/Treatment
ginseng ixeris of sonchifolia hance ...Study Participants
120The purpose of this study is to investigate the efficacy of fractions-based herbal combinations of clearing heat and promoting blood circulation treating acute ischemic stroke and the potential mechanism of it.
The interaction between fire-heat and blood stasis is a significant mechanism underlying pathogenesis and progress in acute ischemic stroke according to TCM theory.Clinical therapeutic effects are achieved with wide application of Ixeris of sonchifolia Hance components (KDZ injection) representing method of clearing heat and Panax notoginseng saponins components (Xueshuantong injection) representing method of promoting blood circulation.
KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
Comply to the Chinese guidelines of acute ischemic stroke in 2010
Treat with KDZ injection on the basis of the basic treatment
Treat with Xueshuantong injection on the basis of the basic treatment
Treat with both KDZ injection and Xueshuantong injection on the basis of the basic treatment
Inclusion Criteria: Patients with acute ischemic stroke Patients with fire-heat syndrome Stoke onset within 48 hours NIHSS scores range from 5 points to 25 points Age from forty to seventy-five,gender not limited Informed and signed the consent Exclusion Criteria: Cardiogenic cerebral embolism,stroke caused by other reasons or the unexplained Patients suitable for thrombolytic therapy(rt-PA, urokinase) Patients have received thrombolytic therapy Patients with serious diseases of heart,lungs,liver,kidneys Patients with bleeding or bleeding tendency recently Pregnant or lactating women Pre-existing neurological or psychiatric diseases that could confound the study results Patients be allergic to alcohol,Ixeris of sonchifolia Hance components (KDZ injection) or Panax notoginseng saponins components (Xueshuantong injection) Patients have participated in other clinical trials within 3 months